Gynecologic Cancer Survival Rates at High-Volume Centers
(HealthDay News) — For women with gynecologic cancers, treatment at high-volume centers is associated with a survival advantage, according to a study presented at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer, held from March 22–25 in Tampa, FL.
Jeff F. Lin, MD, from the Magee-Women's Hospital at the University of Pittsburgh Medical Center, and colleagues used the National Cancer Data Base to examine the characteristics and outcomes of centers treating high volumes of gynecologic cancer patients. A cohort of 863,156 patients with cervical, uterine, ovarian, vaginal, and vulvar cancer who received treatment at 1,666 centers from January 1998–December 2011 were identified. The centers were divided into quartiles based on case volumes.
The researchers found that the lowest quartile centers treated a greater proportion of patients >71 years old and patients with stage IV disease. There was a disease-site survival advantage associated with treatment at top quartile centers, ranging from 2.3–34.1 months compared with the lowest-volume centers (P<0.0005 for all cancers except uterine [P=0.6]). A 10% increased adjusted mortality risk was seen for treatment at lowest-quartile centers.
"Based on this and other studies, we should be trying to steer even more patients to high-volume hospitals," Lin said in a statement.